Zinus is a manufacturer that makes and sells bed mattresses along with bedding and furniture. It established itself in the U.S. online market with compressed, boxed 'roll-pack' mattresses, most of its revenue comes from the United States, and its plant in Indonesia is the key production base. Preliminary Q1 results in May confirmed a sharp revenue drop and widening losses tied to price hikes made in response to U.S. tariffs, and moves to ease the financial burden appeared, such as disposing of subsidiary fixed assets. The notable point is that a P/B of 0.30x and P/S of 0.23x, the cheapest asset and top-line multiples in the peer group, together with a dividend maintained even through a loss-making stretch, are strengths; on the other hand, U.S. tariff uncertainty and an interest-coverage ratio below 1x need to be watched alongside whether quarterly losses narrow.

At-a-glance assessment financial health · growth · profitability · valuation

Financial healthCaution
  • Operating profit barely covers the interest bill (interest coverage below 1x).
  • The most recent full-year net result was a loss.
GrowthDeclining
  • Revenue fell 0.8% year over year (3-year trend: falling).
  • Most recent quarter (Q1 2026) revenue was 44.2% lower than a year earlier.
ProfitabilityLoss-making
  • ROE is -2.9% (controlling-interest basis). It is below the sector average.
  • Operating margin is 2.8%.
ValuationUndervalued
  • P/E is hard to compute here, so this is read on P/B.

Ownership & governance As of 2025-12-31

Largest shareholder Hyundai Department Store 38% (corporate)

Controlling bloc incl. related parties 44.84%

With the controlling bloc holding 45%, the ownership structure is stable.

🔎 In-depth analysis

🏢Business
  • Zinus is a manufacturer that makes and sells bed mattresses along with bedding and furniture.
  • Leading with 'boxed mattresses (roll-pack),' which are compressed, packed into a box, and shipped, it established itself in the U.S. online market, and most of its revenue comes from the United States.
  • The business splits broadly into a mattress segment and a non-mattress segment (bed frames, sofas, furniture), and as of Q1 2026 mattresses are the mainstay, making up more than half of total revenue.
  • Production centers on the plant in Indonesia, with production and logistics bases in the U.S. as well.
  • In short, 'mattresses sold to U.S. consumers' is the revenue axis, so results respond sensitively to U.S. consumer conditions and the trade (tariff) environment.
📈Price & chart
  • The latest close is ₩8,850 and market capitalization is ₩194.0 billion.
  • The price sits below its 20-day line (₩9,216) and below its 60-day line (₩10,540).
  • Trading below both its short- and medium-term moving averages, the trend looks subdued.
  • The RSI (a supplementary gauge comparing upward and downward momentum over the past 14 days on a 0-100 scale) is 39.5, a neutral level.
  • The 1-month change is -4.7%, the 3-month change is -16.4%, and it stands -59.2% below its 52-week high.
  • Relative strength versus KOSPI is 4 (1-99, converting the past year's return against the index with more weight on recent performance; higher means stronger than the market).
  • It sits in roughly the top 97% of all stocks by strength.
  • Over the past three months it lagged the index by 35.1%.
  • Chart interpretation is best done alongside trading volume and disclosure dates.
📊Key metrics
  • The most striking feature is the price relative to assets.
  • The P/B (how many times book value per share the price represents) is 0.30x, meaning the price is about a third of book value per share (BPS) of ₩29,617, and the P/S (how many times a year's revenue the price represents) is also very low at 0.23x.
  • Even against peers, it is below Ace Bed and Fursys (each P/B 0.46x) and Hanssem (1.91x), the cheapest position in the peer group on an asset basis.
  • The dividend has not stopped either, paying ₩90 per share (a dividend yield of about 1.0%).
  • Profitability, by contrast, is weak.
  • The 2025 operating margin was 2.8%, so the operating line was in the black, but net profit was a loss, which puts ROE (how much it earns in a year on capital) at -2.9% and leaves the P/E (how many times a year's profit the price represents) uncomputable because of the loss.
  • On the financial side, a debt ratio of 165% and an interest-coverage ratio of 0.48x, which makes it tight to cover interest fully from operating profit, are a clear weakness, but a current ratio of 194% leaves short-term payment capacity ample.
  • In sum, the crux is 'clearly cheap relative to assets and revenue, but not currently earning a profit.' A low P/B in itself need not be seen as a burden; it is a discount with large room for re-valuation if profit normalizes.
🚀Growth
  • Revenue over five years eased gently from ₩1,123.8 billion in 2021 to ₩913.2 billion in 2025, an annual trend of about -5%, while profit shifted from black in 2021-2022 to sharply reduced and then loss-making from 2023.
  • In 2025 operating profit returned to black at ₩25.4 billion, but net profit stayed in the red at -₩18.5 billion.
  • The decisive inflection was Q1 2026, when revenue fell 44% year on year, the operating loss was -₩30.1 billion, and the net loss was -₩22.8 billion, so a single quarter's loss exceeded the whole prior year's loss.
  • The cause is clear.
  • Price hikes made in response to U.S. tariffs immediately led to weaker mattress orders, and as utilization at the key Indonesia plant fell, the fixed-cost burden grew.
  • For this reason, no basis has yet been confirmed for putting this year's (forward) net profit in positive territory, so no forward P/E is presented.
  • In short, the key from a growth standpoint is 'whether mattress orders and plant utilization recover as U.S. demand and the tariff environment stabilize,' and until then an earnings recovery is hard to call.
📰Recent news & filings
  • Recent disclosures concentrate on the earnings shock and financial-structure management.
  • On May 6 preliminary Q1 results (fair disclosure) officially confirmed the sharp revenue drop and widening loss, and on May 22 a decision to dispose of a subsidiary's (overseas entity's) fixed assets was disclosed, signaling a move to ease the financial burden through asset sales.
  • These were followed by an April 22 pre-announcement of earnings-settlement disclosure and an investor relations (IR) event, a May 15 quarterly report, and a June 4 report on a change in a large-holding stake.
  • That several 'decisions on debt guarantees for third parties' disclosures came out from April onward signals active funding and guarantee activity, a point to view alongside the debt ratio.
🧭Bottom line
  • Starting with the strengths, the price is about a third of book value (P/B 0.30x) and a quarter of revenue (P/S 0.23x), the cheapest position in the peer group on an asset and top-line basis; it maintains a dividend even in a loss-making stretch; and at roughly half its 52-week high it has priced in much of the bad news.
  • Moves to lighten the balance sheet, such as disposing of subsidiary assets, are also under way.
  • The cautions are just as clear.
  • Price hikes in response to U.S. tariffs led to weaker mattress demand, so the Q1 loss exceeded the whole prior year's loss, and with an interest-coverage ratio below 1x it is tight to cover interest from operating profit.
  • In sum, when U.S. demand and the tariff environment stabilize and mattress orders and plant utilization recover, the low asset multiple has large room to be re-valued; conversely, if tariff uncertainty drags on and losses accumulate, the discount could become more justified.
  • The key variables separating strength from weakness are 'normalization of U.S. demand and tariffs' and 'a turn to narrowing quarterly losses.'

🔎 Valuation vs peers Inconclusive

Domestic bed and furniture manufacturers; direct mattress competitor Ace Bed, interior-and-furniture player Hanssem, and furniture maker Fursys are taken as the peer group.

PeerP/EP/BROE
Ace Bed6.28x0.47x7.48%
Hanssem17.90x2.07x11.58%
Fursys8.81x0.52x5.95%

On an asset and revenue basis it sits at the cheapest position in the peer group (P/B 0.33x), but much of this discount stems from the fact that it is 'not earning a profit.' With 2025 net profit a loss there is no trailing P/E, and at a loss-making inflection a multiple based on past results is hard to make meaningful. Peers Ace Bed and Fursys sit around a P/B of 0.5x but with positive ROE (7.5% and 5.9% respectively), so their low P/B differs in character from Zinus's, where 'there is a reason for being cheap.' If U.S. tariffs and demand normalize and the loss turns to profit, there is room for the low asset multiple to be re-valued, but if the sharp widening of the Q1 loss continues, the discount could be justified, so it cannot be decisively called either way.

₩8,850 -1.34%
Market cap $128.6M

Price history Close · MA20 · MA60

Close MA20MA60

The latest close is ₩8,850 and the market capitalization is ₩194.0 billion. The price sits below its 20-day moving average (₩9,216) and below its 60-day moving average (₩10,540). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 39.5, a neutral level. The one-month change is -4.7%, the three-month change is -16.4%, and the position relative to the 52-week high is -59.2%. Relative strength versus the KOSPI is 4 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 3% of all stocks. Over the past three months it lagged the index by 35.1%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.

Relative performance stock vs index · start = 100

4Relative strength vs KOSPI1–99 · last 12 months’ return vs the index, recency-weighted · higher = stronger than the marketTop 97% strength

Excess return vs index · 3M -35.15% / 6M -54.00% / 12M -79.33%

StockKOSPI

Key metrics vs whole-market median

Valuation

P/E (trailing)
P/B0.30x
P/S0.24x
EPS₩-844
BPS (book value/share)₩29,617
Dividend yield1.02%
DPS₩90

A net loss makes the P/E an unreliable valuation gauge. The P/B of 0.30x is below the whole-market median (1.15x).

Enterprise value (EV)

Net debt-$84.5M
EV (enterprise value)$44.3M
EV/EBIT2.62x
EV/EBITDA0.67x
EV/Sales0.07x
FCF (free cash flow)$108.3M
FCF yield84.09%

EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.

Profitability & financials

ROE-2.85%
Operating margin2.79%
Net margin-2.03%
Debt ratio165.26%
Payout ratio

Return on equity (ROE) is -2.9%, below the whole-market average (5.0%). The operating margin is 2.8%. The debt ratio is 165.3%, so the financial structure is moderate.

Growth FY2025 · annual report (consolidated)

Item202320242025YoY
Revenue$631.1M$610.0M$605.2M-0.78% ↑ faster
Operating profit$12.2M-$3.6M$16.9M
Net profit$3.5M-$4.5M-$12.3M
5-year20212022202320242025
Revenue$744.9M$768.6M$631.1M$610.0M$605.2M
Operating profit$49.3M$43.5M$12.2M-$3.6M$16.9M
Net profit$34.2M$19.5M$3.5M-$4.5M-$12.3M
Revenue CAGR4-yr avg -5.06%

Revenue fell 0.8% year over year (2023 ₩952.3 billion → 2024 ₩920.4 billion → 2025 ₩913.2 billion), and the three-year trend is 'falling'. That said, the rate of decline narrowed from the prior year. Over the 5 years on record, revenue compound annual growth (CAGR) is -5.1%. The two-year revenue CAGR is -2.1%. In the most recent quarter (Q1 2026), revenue was 44.2% lower than the same period a year earlier.

Latest quarterly results Q1 2026 · vs year-ago

Revenue$92.5M
Revenue YoY-44.16%
Operating profit-$19.9M
Op. profit YoY-209.42%
Net profit-$15.1M
Net profit YoY-222.35%

Technical indicators

RSI (14)39.5
MA20₩9,216
MA60₩10,540
1-month-4.74%
3-month-16.43%
vs 52-wk high-59.22%

What stands out

  • P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.

Points to watch

  • Operating profit barely covers the interest bill (interest coverage below 1x).
  • The most recent full-year net result was a loss.
  • The most recent full year was a loss, so it is worth checking whether profitability recovers.
  • Revenue fell 0.8% year over year (3-year trend: falling).

Recent news & events searched · sourced

Figure cross-check computed ↔ external

MetricComputedExternalStatusSource
Q1 2026 consolidated revenue / net lossrevenue 1,395.6(YoY -44.2%), -300.9, -228.2DART 2026-05-06Confirmedlink
2025 full-year results (revenue / operating profit / net profit)revenue 9,132, operating profit 254.8, -185.1DART 2026-05-15Confirmedlink
Fact of subsidiary fixed-asset disposalDART 2026-05-22Confirmedlink

Recent filings

📖 Plain-language glossary — expand if you are new to this
P/E
How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
P/B
Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
P/S
Price relative to a year's revenue — useful for growth companies with thin earnings.
Net debt / EV
Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
EV/EBIT · EV/EBITDA · EV/Sales
Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
FCF / FCF yield
Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
Intrinsic value (DCF)
Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
ROE
How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
EPS / BPS
Earnings per share / net assets (book value) per share.
Operating / net margin
Profit left from the core business / final profit after tax and interest, per unit of revenue.
Debt ratio
Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
Current ratio
Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
Interest coverage
How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
Dividend yield / payout ratio
The year's dividend as a % of today's price / the share of earnings paid out as dividends.
Revenue CAGR
Multi-year growth expressed as a single yearly average (compound annual growth rate).
RSI (short-term signal)
Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
MA20 / MA60 (moving averages)
The 20- and 60-day average price. Price above them signals a firmer short-term trend.
vs 52-week high
How far below the past year's peak the price sits now (%).

All figures are for reference only; how they read varies by sector and over time.

Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.

Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.